Latest from Yale Cancer Center

Charles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, discusses immunotherapy in gastric cancer.
Inspired by the long tradition of innovation at Yale University, particularly in the life sciences, The Blavatnik Family Foundation has donated $10million to Yale University to promote and to accelerate the development, application, and commercialization of breakthrough research in the life sciences.
The Yale School of Medicine, partnering with Yale New Haven Hospital, took the next step toward personalized medicine, cutting the ribbon on its Center for Genome Analysis on Yales West Campus.
Radiotherapy alone is often used to treat early-stage glottic cancer, a cancer of the vocal chords, however, the optimal radiation treatment schedule remains unknown.
In some cases, the Lassa virus starts with a fever and general weakness, moving toward headache, muscle pain, possible facial swelling, deafness, and worse. About 15 percent of patients hospitalized with severe cases die.
An early round of clinical testing shows that users of nivolumab (Opdivo), a drug sanctioned for treatment of small-cell lung cancer, more than tripled their five-year survival rate beyond the statistical average.
Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancer, discusses the KEYNOTE-045 trial investigating pembrolizumab (Keytruda) versus physician’s choice of chemotherapy for patients with urothelial carcinoma.
Publication Bottom Border
Border Publication